Roots Analysis

FEBRUARY 18, 2022

Over time, many research studies have shown that myeloid cells can interact with the immune system and aid in generating an appropriate anti-tumor immune response. CLINICAL TRIALS EVALUATING MYELOID CELLS TAREGTING THERAPEUTICS. The key focus of these studies is on the development of anti-tumor therapeutics.

Drug Delivery Systems 52

Drug Delivery Systems Immune Response Clinical Trials Clinical Trials 52

Roots Analysis

MARCH 3, 2022

The complement-targeted therapeutics inhibit complement activation, thereby reducing tissue inflammation and dampening the adaptive immune response to foreign and tissue antigens. Broad Clinical Trial Landscape. Next Generation Complement Therapeutics – Current Market Landscape. Next Generation Complement Therapeutics.

Drug Delivery Systems 52

Drug Delivery Systems Marketing Immune Response Dermatology 52

Roots Analysis

MAY 21, 2024

In addition, NLCs offer benefits such as high drug loading capacity, improved drug retention and avoidance of drug expulsion. Advantages of Lipid Nanoparticle LNPs are gaining significant attention of formulation scientists in drug delivery due to the various advantages offered by them.

Drug Delivery 40

Drug Delivery Drugs Gene Therapy Bioavailability 40

Drug Discovery World

FEBRUARY 5, 2024

Dr Gen Li, Founder and President, Phesi “In 2024, we can expect immunotherapy trials to become a driving force for change in clinical development. In the past 10 years, immunotherapy trials have increased by 430%. Due to the precision and specificity of immunotherapies, there are fewer available patients for clinical trials.

Research 116

Research Gene Sequencing Drug Delivery Systems Trials 116